Wednesday, March 22, 2023
Home Biotech News 2021 Watch List

2021 Watch List

    Latest

    Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy.

    2021 Watch List Editor / Curator -
    Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or...
    Biotech Stock Review

    Citius Pharma (CTXR) Flexes Muscle in Business Update. Remains Our Top Idea.

    2021 Watch List Editor / Curator -
    Added to Watch List November 2019 @$0.55. Named Our Top Idea in 2020 @$1.02.Remains Our Top Idea in 2021...

    Hapbee (HAPB) Expands Leadership Team to Support Aggressive Growth Strategy

    Featured Editor / Curator -
    VANCOUVER, BC, Aug. 6, 2021 /CNW/ - Hapbee Technologies, Inc. (TSXV: HAPB) (OTCQB: HAPBF) (FSE: HA1) ("Hapbee" or the "Company"), the leading wearable, wellness technology company has...

    Citius Pharma (CTXR) $2.15. Price Target of $8.00 Maintained, Post Safety and Efficacy Review.

    Biotech News Editor / Curator -
    Investment Banker Buy Rating Maintained: DSMB Gives the Thumbs Up – Data in Early 2022. CITIUS NEWS ARCHIVE

    Preventing Type I Diabetes. Here’s How Provention (PRVB) Works.

    Biotech News Editor / Curator -
    Here's How Provention's Treatment Works. Interview With an Actual Provention Bio (PRVB) Clinical Trial Participant.
    @bryteeyes3

    Citius (CTXR). Dang Flippers!

    Biotech News Editor / Curator -
    Short term investors powered Citius from $2.50 to near $4.50 in hopes of a positive early trial...
    Provention

    Teplizumab: Can We Delay the Onset of Type 1? (DiaTribe)

    Diabetes Editor / Curator -
    Teplizumab: Can We Delay the Onset of Type 1? Last updated: 6/7/21 By Dr. Francine...
    @NCI

    Citius (CTXR) Expands Scientific Advisory Board. Dr. John Laffey, Expert in Stem Cell and...

    CoronaVirus Editor / Curator -
    - Addition of leading scholar and KOL in acute respiratory distress syndrome (ARDS) to ARDS Scientific Advisory Board supports continued progress of...
    Biotech Stock Review. Citius, CTXR

    More Great News From Citius Pharma (CTXR).

    Incubator Editor / Curator -
    UPDATED CHART 6-15-21 Mino-Lok® Phase III, FDA NewsRussell 2000 Index NewsTechnical Breakout News
    Internet Stock Review

    Stocks On The Move!

    2021 Watch List Editor / Curator -
    Citius (CTXR) up 19%, Draganfly (DFLYF) up 31%, urban-gro (UGRO) up 37%, Provention (PVRB) flip-flopping, Hapbee Technologies (HAPBF) up 26% and the...
    12Page 1 of 2

    Latest article

    IA Initiates Analyst Coverage of Principal Solar (Press Release).

    Alternative Energy Editor / Curator -
    Principal Solar, Inc.Mon, March 20, 2023 at 7:30 AM EDT Institutional Analyst, Inc....

    Selling ARK (ARKK) & Buying AXS Short Innovation (SARK) ETF.

    All News Editor / Curator -
    Going Short the Market. No Long Dissertation, No Rush. Market Risk Has Appeared, With Minimal Upside, So Time To Act.

    We’re Bearish, but we’re up 257% in Provention Bio (PRVB) Today.

    2022 Watch List Editor / Curator -
    And up 416%, from Adding it to 2022 Watch List! Great way to wake up after a night of...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: roland@institutionalanalyst.com
    © Managed by Revelers.IO Media Group Inc.